324 related articles for article (PubMed ID: 28855508)
21. Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators.
Estabrooks S; Brodsky JL
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936842
[TBL] [Abstract][Full Text] [Related]
22. Non-native Conformers of Cystic Fibrosis Transmembrane Conductance Regulator NBD1 Are Recognized by Hsp27 and Conjugated to SUMO-2 for Degradation.
Gong X; Ahner A; Roldan A; Lukacs GL; Thibodeau PH; Frizzell RA
J Biol Chem; 2016 Jan; 291(4):2004-2017. PubMed ID: 26627832
[TBL] [Abstract][Full Text] [Related]
23. A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo.
French PJ; van Doorninck JH; Peters RH; Verbeek E; Ameen NA; Marino CR; de Jonge HR; Bijman J; Scholte BJ
J Clin Invest; 1996 Sep; 98(6):1304-12. PubMed ID: 8823295
[TBL] [Abstract][Full Text] [Related]
24. Cystic fibrosis transmembrane conductance regulator degradation: cross-talk between the ubiquitylation and SUMOylation pathways.
Ahner A; Gong X; Frizzell RA
FEBS J; 2013 Sep; 280(18):4430-8. PubMed ID: 23809253
[TBL] [Abstract][Full Text] [Related]
25. Strategies for correcting the delta F508 CFTR protein-folding defect.
Brown CR; Hong-Brown LQ; Welch WJ
J Bioenerg Biomembr; 1997 Oct; 29(5):491-502. PubMed ID: 9511934
[TBL] [Abstract][Full Text] [Related]
26. Biosynthesis and degradation of CFTR.
Kopito RR
Physiol Rev; 1999 Jan; 79(1 Suppl):S167-73. PubMed ID: 9922380
[TBL] [Abstract][Full Text] [Related]
27. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
[TBL] [Abstract][Full Text] [Related]
28. A small molecule that binds to an ATPase domain of Hsc70 promotes membrane trafficking of mutant cystic fibrosis transmembrane conductance regulator.
Cho HJ; Gee HY; Baek KH; Ko SK; Park JM; Lee H; Kim ND; Lee MG; Shin I
J Am Chem Soc; 2011 Dec; 133(50):20267-76. PubMed ID: 22074182
[TBL] [Abstract][Full Text] [Related]
29. Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR.
Zhang F; Kartner N; Lukacs GL
Nat Struct Biol; 1998 Mar; 5(3):180-3. PubMed ID: 9501909
[TBL] [Abstract][Full Text] [Related]
30. Hsp70 and DNAJA2 limit CFTR levels through degradation.
Kim Chiaw P; Hantouche C; Wong MJH; Matthes E; Robert R; Hanrahan JW; Shrier A; Young JC
PLoS One; 2019; 14(8):e0220984. PubMed ID: 31408507
[TBL] [Abstract][Full Text] [Related]
31. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.
Denning GM; Anderson MP; Amara JF; Marshall J; Smith AE; Welsh MJ
Nature; 1992 Aug; 358(6389):761-4. PubMed ID: 1380673
[TBL] [Abstract][Full Text] [Related]
32. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR.
Rubenstein RC; Zeitlin PL
Am J Physiol Cell Physiol; 2000 Feb; 278(2):C259-67. PubMed ID: 10666020
[TBL] [Abstract][Full Text] [Related]
33. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
Amaral MD
Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
[TBL] [Abstract][Full Text] [Related]
34. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids.
Lim M; McKenzie K; Floyd AD; Kwon E; Zeitlin PL
Am J Respir Cell Mol Biol; 2004 Sep; 31(3):351-7. PubMed ID: 15191910
[TBL] [Abstract][Full Text] [Related]
35. F508del-CFTR rescue: a matter of cell stress response.
Nieddu E; Pollarolo B; Merello L; Schenone S; Mazzei M
Curr Pharm Des; 2013; 19(19):3476-96. PubMed ID: 23331026
[TBL] [Abstract][Full Text] [Related]
36. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
Roxo-Rosa M; Xu Z; Schmidt A; Neto M; Cai Z; Soares CM; Sheppard DN; Amaral MD
Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17891-6. PubMed ID: 17098864
[TBL] [Abstract][Full Text] [Related]
37. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.
Strub MD; McCray PB
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011
[TBL] [Abstract][Full Text] [Related]
38. From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking.
Farinha CM; Canato S
Cell Mol Life Sci; 2017 Jan; 74(1):39-55. PubMed ID: 27699454
[TBL] [Abstract][Full Text] [Related]
39. The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability.
Meng X; Clews J; Kargas V; Wang X; Ford RC
Cell Mol Life Sci; 2017 Jan; 74(1):23-38. PubMed ID: 27734094
[TBL] [Abstract][Full Text] [Related]
40. Cystic fibrosis: a disease of altered protein folding.
Qu BH; Strickland E; Thomas PJ
J Bioenerg Biomembr; 1997 Oct; 29(5):483-90. PubMed ID: 9511933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
